Skip to content

Screener

Eligibility screening

A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.Study detailsClinicalTrials.gov

11 US sites in CO, CT, FL, NV +2

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.